Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality.
CONCLUSION: We conclude that COVID-19+ patients with moderate or severe illness benefit from anticoagulation and that apixaban has similar efficacy to enoxaparin in decreasing mortality in this disease.
PMID: 33186991 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Billett HH, Reyes-Gil M, Szymanski J, Ikemura K, Stahl LR, Lo Y, Rahman S, Gonzalez-Lugo JD, Kushnir M, Barouqa M, Golestaneh L, Bellin E Tags: Thromb Haemost Source Type: research
More News: Clinical Trials | Coronavirus | COVID-19 | Hematology | Intensive Care | Lovenox | Study | Thrombosis